fluorouracil has been researched along with Dermatoses in 104 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Excerpt | Relevance | Reference |
---|---|---|
"The addition of sorafenib to gemcitabine/capecitabine provided a clinically small but statistically significant PFS benefit in HER2-negative advanced breast cancer patients whose disease progressed during/after bevacizumab." | 9.17 | Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab. ( Beck, JT; Bell-McGuinn, K; Eisenberg, P; Emanuelson, R; Hermann, RC; Hudis, CA; Isaacs, C; Kaklamani, V; Keaton, M; Kirshner, JJ; Levine, E; Lokker, NA; Makari-Judson, G; Medgyesy, DC; Qamar, R; Ro, SK; Rugo, HS; Schwartzberg, LS; Starr, A; Stepanski, EJ; Tauer, KW; Wang, W, 2013) |
"The AIO KRK-0104 randomised phase II trial investigated the efficacy and safety of two capecitabine-based regimens: combination of capecitabine and irinotecan (CAPIRI) plus cetuximab (CAPIRI-C) and combination of capecitabine with oxaliplatin (CAPOX) plus cetuximab (CAPOX-C) in the first-line treatment of metastatic colorectal cancer (mCRC)." | 9.15 | Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial. ( Abenhardt, W; Decker, T; Dietzfelbinger, H; Fischer von Weikersthal, L; Giessen, C; Haberl, C; Hass, HG; Heinemann, V; Kappauf, H; Klein, S; Mittermüller, J; Moosmann, N; Oruzio, D; Puchtler, G; Schulze, M; Stauch, M; Stintzing, S; Vehling-Kaiser, U; Zellmann, K, 2011) |
"We report severe skin toxicity observed in anthracycline-pretreated metastatic breast cancer patients receiving the combination of capecitabine and weekly paclitaxel." | 9.13 | Severe skin toxicity observed with the combination of capecitabine and weekly paclitaxel in metastatic breast cancer patients. ( Bosnjak, SM; Radulovic, S; Susnjar, S, 2008) |
"We retrospectively reviewed the records of 141 consecutive patients with metastatic breast cancer identified from pharmacy records as receiving capecitabine outside of a clinical trial between May 1998 and February 1999." | 8.82 | Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature. ( Gauthier, AM; Hennessy, BT; Hortobagyi, G; Michaud, LB; Valero, V, 2005) |
"Capecitabine is one of the most effective oral regimens of chemotherapy against advanced or recurrent breast cancer." | 7.74 | [Management of hand-foot syndrome in patient treated with capecitabine]. ( Anami, S; Fujii, C; Fujino, M; Fujita, M; Furukawa, H; Inoue, M; Kamigaki, S; Nakayama, T; Tatsuta, M; Yasui, Y, 2008) |
"We present a case of hand-foot syndrome (HFS) induced by bolus 5-fluorouracil (5-FU) therapy." | 7.74 | [A case report of a patient with hand-foot syndrome induced by bolus 5-fluorouracil therapy]. ( Aoyagi, H; Enomoto, M; Higuchi, T; Iida, S; Ishikawa, T; Kobayashi, H; Matsuyama, T; Sugihara, K; Uetake, H; Yasuno, M, 2008) |
"The combined use of ablative Er:YAG laser and topical 5-fluorouracil chemotherapy may be considered as an effective treatment option in cases of giant keratoacanthoma when conventional surgery is not indicated." | 7.72 | Combined 5-fluorouracil and Er:YAG laser treatment in a case of recurrent giant keratoacanthoma of the lower leg. ( Elsner, P; Fuchs, S; Thiele, JJ; Ziemer, M, 2004) |
" The most commonly observed adverse events by KRAS tumor status included dermatitis acneiform and pruritus." | 6.76 | The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status. ( Iannotti, N; Lacouture, ME; Mitchell, EP; Pillai, MV; Piperdi, B; Shearer, H; Xu, F; Yassine, M, 2011) |
"Keratoacanthoma is a common, benign cutaneous neoplasm that displays rapid growth on sun-exposed skin." | 5.31 | Topical 5-fluorouracil as primary therapy for keratoacanthoma. ( Gray, RJ; Meland, NB, 2000) |
"A keratoacanthoma is a benign epithelial growth most often found in sun-exposed skin of the elderly." | 5.26 | Treatment of multiple keratoacanthomas with intralesional fluorouracil. ( Eubanks, SW; Gentry, RH; May, DL; Patterson, JW, 1982) |
"The addition of sorafenib to gemcitabine/capecitabine provided a clinically small but statistically significant PFS benefit in HER2-negative advanced breast cancer patients whose disease progressed during/after bevacizumab." | 5.17 | Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab. ( Beck, JT; Bell-McGuinn, K; Eisenberg, P; Emanuelson, R; Hermann, RC; Hudis, CA; Isaacs, C; Kaklamani, V; Keaton, M; Kirshner, JJ; Levine, E; Lokker, NA; Makari-Judson, G; Medgyesy, DC; Qamar, R; Ro, SK; Rugo, HS; Schwartzberg, LS; Starr, A; Stepanski, EJ; Tauer, KW; Wang, W, 2013) |
"The AIO KRK-0104 randomised phase II trial investigated the efficacy and safety of two capecitabine-based regimens: combination of capecitabine and irinotecan (CAPIRI) plus cetuximab (CAPIRI-C) and combination of capecitabine with oxaliplatin (CAPOX) plus cetuximab (CAPOX-C) in the first-line treatment of metastatic colorectal cancer (mCRC)." | 5.15 | Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial. ( Abenhardt, W; Decker, T; Dietzfelbinger, H; Fischer von Weikersthal, L; Giessen, C; Haberl, C; Hass, HG; Heinemann, V; Kappauf, H; Klein, S; Mittermüller, J; Moosmann, N; Oruzio, D; Puchtler, G; Schulze, M; Stauch, M; Stintzing, S; Vehling-Kaiser, U; Zellmann, K, 2011) |
"We report severe skin toxicity observed in anthracycline-pretreated metastatic breast cancer patients receiving the combination of capecitabine and weekly paclitaxel." | 5.13 | Severe skin toxicity observed with the combination of capecitabine and weekly paclitaxel in metastatic breast cancer patients. ( Bosnjak, SM; Radulovic, S; Susnjar, S, 2008) |
"We retrospectively reviewed the records of 141 consecutive patients with metastatic breast cancer identified from pharmacy records as receiving capecitabine outside of a clinical trial between May 1998 and February 1999." | 4.82 | Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature. ( Gauthier, AM; Hennessy, BT; Hortobagyi, G; Michaud, LB; Valero, V, 2005) |
"Capecitabine is one of the most effective oral regimens of chemotherapy against advanced or recurrent breast cancer." | 3.74 | [Management of hand-foot syndrome in patient treated with capecitabine]. ( Anami, S; Fujii, C; Fujino, M; Fujita, M; Furukawa, H; Inoue, M; Kamigaki, S; Nakayama, T; Tatsuta, M; Yasui, Y, 2008) |
"We present a case of hand-foot syndrome (HFS) induced by bolus 5-fluorouracil (5-FU) therapy." | 3.74 | [A case report of a patient with hand-foot syndrome induced by bolus 5-fluorouracil therapy]. ( Aoyagi, H; Enomoto, M; Higuchi, T; Iida, S; Ishikawa, T; Kobayashi, H; Matsuyama, T; Sugihara, K; Uetake, H; Yasuno, M, 2008) |
"The combined use of ablative Er:YAG laser and topical 5-fluorouracil chemotherapy may be considered as an effective treatment option in cases of giant keratoacanthoma when conventional surgery is not indicated." | 3.72 | Combined 5-fluorouracil and Er:YAG laser treatment in a case of recurrent giant keratoacanthoma of the lower leg. ( Elsner, P; Fuchs, S; Thiele, JJ; Ziemer, M, 2004) |
"The effects of cisplatin and 5-fluorouracil on wound breaking strength and the rate of closure of an orocutaneous fistula were studied in 80 male rodents." | 3.68 | The effects of chemotherapy on murine wound healing and orocutaneous fistula closure. ( al-Sarraf, M; Grabow, D; Guan, ZX; Ledgerwood, AM; Lucas, CE; Weaver, A; Whittle, T, 1990) |
" Vitamin A acid and benzoyl peroxide have brought significant advances in the topical treatment of acne." | 3.66 | [Advances in topical therapy of skin diseases (author's transl)]. ( Happle, R, 1979) |
" The most commonly observed adverse events by KRAS tumor status included dermatitis acneiform and pruritus." | 2.76 | The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status. ( Iannotti, N; Lacouture, ME; Mitchell, EP; Pillai, MV; Piperdi, B; Shearer, H; Xu, F; Yassine, M, 2011) |
"Seventy patients with advanced head and neck cancer were treated with vinorelbine and continuous 5-FU administered in a central venous catheter." | 2.73 | A phase II study using vinorelbine and continuous 5-fluorouracil in patients with advanced head and neck cancer. ( Adimi, P; Andersen, LJ; Bastholt, L; Larsen, S; Lindeløv, B; McCulloch, T; Serup-Hansen, E, 2007) |
" In conclusion, capecitabine can safely be combined with docetaxel (40 mg m(-2)) and mitomycin C (4 mg m(-2))." | 2.73 | Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial. ( Ernst, T; Gnad-Vogt, U; Hochhaus, A; Hofheinz, RD; Kripp, M; Lukan, N; Merx, K; Schultheis, B, 2007) |
" In 10 of 19 patients who had not responded (SD, PD), three additional courses of chemotherapy were combined with sCMT (with 25 sCMT applications)." | 2.71 | Whole-body hyperthermia in the scope of von Ardenne's systemic cancer multistep therapy (sCMT) combined with chemotherapy in patients with metastatic colorectal cancer: a phase I/II study. ( Ahlers, O; Deja, M; Dräger, J; Felix, R; Hildebrandt, B; Kerner, T; Löffel, J; Riess, H; Stroszczynski, C; Wust, P, 2004) |
" We investigated the therapeutic and adverse drug reaction of intensive chemotherapy using cisplatin (CDDP), 5-FU and dl-leucovorin (LV) (PFL-therapy), which may be producing dual biochemical modulation effect of 5-FU for advanced colorectal carcinoma." | 2.70 | Investigation into the usefulness and adverse events of CDDP, 5-fU and dl-leucovorin (PFL-therapy) for advanced colorectal cancer. ( Arai, T; Fukahara, T; Ishikawa, T; Iwai, T; Kuwabara, H; Maruyama, S; Murase, N; Okabe, S; Ootsukasa, S; Tanami, H; Udagawa, M; Yamashita, H, 2002) |
"5-fluorouracil (5-FU) has proven to be an effective therapy in the treatment of a variety of dermatologic conditions." | 2.58 | Topical 5-fluorouracil in dermatologic disease. ( Alkousakis, T; Cameron, MC; Fathi, R; Prince, GT, 2018) |
"5-fluorouracil has proven to be an effective therapy in the treatment of a variety of dermatologic conditions." | 2.58 | Intralesional and Laser-Assisted 5-Fluorouracil in Dermatologic Disease: A Systematic Review. ( Alkousakis, T; Cameron, MC; Fathi, R; Prince, GT, 2018) |
"Salicylic acid (SA) was superior to placebo with a risk ratio (RR) for cure of 1·60 [95% confidence interval (CI) 1·15-2·24]." | 2.47 | Efficacy of topical treatments for cutaneous warts: a meta-analysis and pooled analysis of randomized controlled trials. ( Gibbs, S; Holland, R; Kwok, CS, 2011) |
"Combinations for metastatic breast cancer that appear in recently approved labeling include ixabepilone with capecitabine, and the targeted biological agent lapatinib in combination with capecitabine." | 2.45 | Current combination chemotherapy regimens for metastatic breast cancer. ( Schwartz, J, 2009) |
"Lapatinib was administered at doses ranging from 1000 to 1500 mg/day as monotherapy (n=928) or in combination with paclitaxel or capecitabine (n=491)." | 2.45 | Analysis of dermatologic events in patients with cancer treated with lapatinib. ( Blackwell, KL; Byrne, JA; Di Leo, A; Gomez, HL; Koch, KM; Koehler, M; Laabs, SM; Lacouture, ME; Preston, AJ; Salazar, VM; Sweetman, RW, 2009) |
"5 fluorouracil therapy was terminated and the patients were shifted to interferon therapy subsequently." | 1.51 | Severe necrotising inflammatory skin reaction to topical 5-fluorouracil. ( Gokhale, NS, 2019) |
" The frequency of grade 3 and 4 adverse effects were comparatively assessed in each treatment arm." | 1.39 | Comparative assessment of skin and subcutaneous toxicity in patients of advanced colorectal carcinoma treated with different schedules of FOLFOX. ( Bano, N; Mateen, A; Najam, R, 2013) |
"Capecitabine was designed to generate 5FU via the thymidine phosphorylase (TP) enzyme, preferentially expressed in tumoral tissues." | 1.35 | Candidate mechanisms for capecitabine-related hand-foot syndrome. ( Etienne-Grimaldi, MC; Formento, JL; Francoual, M; Hofman, P; Lacour, JP; Lassalle, S; Mari, M; Milano, G, 2008) |
"The clinical diagnosis of multiple pyogenic granulomas was confirmed by histological examination." | 1.33 | Multiple periungual pyogenic granulomas following systemic 5-fluorouracil. ( Cooray, P; Curr, N; Gin, D; Murugasu, A; Saunders, H; Schwarz, M, 2006) |
"Keratoacanthoma is a common, benign cutaneous neoplasm that displays rapid growth on sun-exposed skin." | 1.31 | Topical 5-fluorouracil as primary therapy for keratoacanthoma. ( Gray, RJ; Meland, NB, 2000) |
"5-Fluorouracil (5-FU) is an antimetabolite frequently used in the treatment of cancer." | 1.29 | Dermatological toxicity from chemotherapy containing 5-fluorouracil. ( Campanella, GA; Carrieri, G; Colucci, G; Leo, S; Tatulli, C; Taveri, R, 1994) |
"Diarrhea was the dose-limiting toxic effect and occurred more often in patients with abnormal pretreatment liver function." | 1.27 | Phase I evaluation of oral tegafur. ( Bedikian, AY; Bodey, GP; Burgess, MA; Valdivieso, M, 1983) |
"A keratoacanthoma is a benign epithelial growth most often found in sun-exposed skin of the elderly." | 1.26 | Treatment of multiple keratoacanthomas with intralesional fluorouracil. ( Eubanks, SW; Gentry, RH; May, DL; Patterson, JW, 1982) |
"The 12th case of Bowen's disease, presented here, offers an alternative method of treatment using 5-fluorouracil combined with a keratolytic ointment." | 1.26 | Bowen's disease of the nail bed: a case presentation and review of the literature. ( Defiebre, BK, 1978) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 50 (48.08) | 18.7374 |
1990's | 7 (6.73) | 18.2507 |
2000's | 25 (24.04) | 29.6817 |
2010's | 17 (16.35) | 24.3611 |
2020's | 5 (4.81) | 2.80 |
Authors | Studies |
---|---|
Rivard, SC | 1 |
Soueidy, C | 1 |
Skaff, S | 1 |
Stephan, F | 1 |
Kattan, J | 1 |
Gokhale, NS | 1 |
Gupta, S | 2 |
Jangra, RS | 1 |
Gupta, SS | 1 |
Gujrathi, AV | 1 |
Chiang, TY | 1 |
Hsu, HC | 1 |
Jane, SW | 1 |
Chen, SC | 1 |
Searle, T | 1 |
Al-Niaimi, F | 1 |
Ali, FR | 1 |
Dalenc, F | 1 |
Ribet, V | 1 |
Rossi, AB | 1 |
Guyonnaud, J | 1 |
Bernard-Marty, C | 1 |
de Lafontan, B | 1 |
Salas, S | 1 |
Ranc Royo, AL | 1 |
Sarda, C | 1 |
Levasseur, N | 1 |
Massabeau, C | 1 |
Levecq, JM | 1 |
Dulguerova, P | 1 |
Guerrero, D | 1 |
Sibaud, V | 1 |
Wenande, E | 1 |
Erlendsson, AM | 1 |
Haedersdal, M | 1 |
Prince, GT | 2 |
Cameron, MC | 2 |
Fathi, R | 2 |
Alkousakis, T | 2 |
Takada, S | 1 |
Sagawa, T | 1 |
Fujikawa, K | 1 |
Tahatsu, K | 1 |
Fukai, Y | 1 |
Hashishita, H | 1 |
Takahashi, Y | 1 |
Endo, M | 1 |
Schwartzberg, LS | 1 |
Tauer, KW | 1 |
Hermann, RC | 1 |
Makari-Judson, G | 1 |
Isaacs, C | 1 |
Beck, JT | 1 |
Kaklamani, V | 1 |
Stepanski, EJ | 1 |
Rugo, HS | 1 |
Wang, W | 1 |
Bell-McGuinn, K | 1 |
Kirshner, JJ | 1 |
Eisenberg, P | 1 |
Emanuelson, R | 1 |
Keaton, M | 1 |
Levine, E | 1 |
Medgyesy, DC | 1 |
Qamar, R | 1 |
Starr, A | 1 |
Ro, SK | 1 |
Lokker, NA | 1 |
Hudis, CA | 1 |
Bano, N | 1 |
Najam, R | 1 |
Mateen, A | 1 |
Comfere, NI | 1 |
Ikediobi, ON | 1 |
Peters, MS | 1 |
el-Azhary, RA | 1 |
Gibson, LE | 1 |
Peeters, M | 1 |
Price, TJ | 1 |
Cervantes, A | 1 |
Sobrero, AF | 1 |
Ducreux, M | 1 |
Hotko, Y | 1 |
André, T | 1 |
Chan, E | 1 |
Lordick, F | 1 |
Punt, CJ | 1 |
Strickland, AH | 1 |
Wilson, G | 1 |
Ciuleanu, TE | 1 |
Roman, L | 1 |
Van Cutsem, E | 1 |
Tian, Y | 1 |
Sidhu, R | 1 |
Yeung, R | 1 |
McConnell, Y | 1 |
Warkentin, H | 1 |
Graham, D | 1 |
Warkentin, B | 1 |
Joseph, K | 1 |
Doll, CM | 1 |
Ardavanis, A | 1 |
Orphanos, G | 1 |
Skafida, S | 1 |
Basioukas, S | 1 |
Rigatos, G | 1 |
Lacouture, ME | 2 |
Laabs, SM | 1 |
Koehler, M | 1 |
Sweetman, RW | 1 |
Preston, AJ | 1 |
Di Leo, A | 1 |
Gomez, HL | 1 |
Salazar, VM | 1 |
Byrne, JA | 1 |
Koch, KM | 1 |
Blackwell, KL | 1 |
Fujii, C | 1 |
Anami, S | 1 |
Fujino, M | 1 |
Yasui, Y | 1 |
Fujita, M | 1 |
Inoue, M | 1 |
Nakayama, T | 1 |
Kamigaki, S | 1 |
Tatsuta, M | 1 |
Furukawa, H | 1 |
Susnjar, S | 1 |
Bosnjak, SM | 1 |
Radulovic, S | 1 |
Matsuyama, T | 1 |
Uetake, H | 1 |
Aoyagi, H | 1 |
Kobayashi, H | 1 |
Ishikawa, T | 2 |
Iida, S | 1 |
Higuchi, T | 1 |
Yasuno, M | 1 |
Enomoto, M | 1 |
Sugihara, K | 1 |
Lee, YJ | 1 |
Lee, HJ | 1 |
Jeong, KC | 1 |
Kang, JG | 1 |
Lee, SH | 1 |
Kim, YT | 1 |
Vano-Galvan, S | 1 |
Moreno, C | 1 |
Medina, J | 1 |
Pérez-García, B | 1 |
García-López, JL | 1 |
Jaén, P | 1 |
Schwartz, J | 1 |
Moore, AY | 1 |
Ceilley, RI | 1 |
Kwok, CS | 1 |
Holland, R | 1 |
Gibbs, S | 1 |
Grossberg, AL | 1 |
Gaspari, AA | 1 |
Stintzing, S | 1 |
Fischer von Weikersthal, L | 1 |
Vehling-Kaiser, U | 1 |
Stauch, M | 1 |
Hass, HG | 1 |
Dietzfelbinger, H | 1 |
Oruzio, D | 1 |
Klein, S | 1 |
Zellmann, K | 1 |
Decker, T | 1 |
Schulze, M | 1 |
Abenhardt, W | 1 |
Puchtler, G | 1 |
Kappauf, H | 1 |
Mittermüller, J | 1 |
Haberl, C | 1 |
Giessen, C | 1 |
Moosmann, N | 1 |
Heinemann, V | 1 |
Mitchell, EP | 1 |
Piperdi, B | 1 |
Shearer, H | 1 |
Iannotti, N | 1 |
Pillai, MV | 1 |
Xu, F | 1 |
Yassine, M | 1 |
Thaler, J | 1 |
Karthaus, M | 1 |
Mineur, L | 1 |
Greil, R | 1 |
Letocha, H | 1 |
Hofheinz, R | 1 |
Fernebro, E | 1 |
Gamelin, E | 1 |
Baños, A | 1 |
Köhne, CH | 1 |
Okabe, S | 1 |
Tanami, H | 1 |
Kuwabara, H | 1 |
Fukahara, T | 1 |
Udagawa, M | 1 |
Ootsukasa, S | 1 |
Arai, T | 1 |
Maruyama, S | 1 |
Murase, N | 1 |
Yamashita, H | 1 |
Iwai, T | 1 |
Blugerman, G | 1 |
Schavelzon, D | 1 |
Dreszman, R | 1 |
Hildebrandt, B | 1 |
Dräger, J | 1 |
Kerner, T | 1 |
Deja, M | 1 |
Löffel, J | 1 |
Stroszczynski, C | 1 |
Ahlers, O | 1 |
Felix, R | 1 |
Riess, H | 1 |
Wust, P | 1 |
Thiele, JJ | 1 |
Ziemer, M | 1 |
Fuchs, S | 1 |
Elsner, P | 1 |
Larkö, O | 1 |
Hennessy, BT | 1 |
Gauthier, AM | 1 |
Michaud, LB | 1 |
Hortobagyi, G | 1 |
Valero, V | 1 |
Davis, MD | 1 |
Weick, JA | 1 |
Link, JS | 1 |
Yuge, S | 1 |
Godoy, DA | 1 |
Melo, MC | 1 |
Sousa, DS | 1 |
Soares, CT | 1 |
Curr, N | 1 |
Saunders, H | 1 |
Murugasu, A | 1 |
Cooray, P | 1 |
Schwarz, M | 1 |
Gin, D | 1 |
Poligone, B | 1 |
Christensen, SR | 1 |
Lazova, R | 1 |
Heald, PW | 1 |
Larsen, S | 1 |
Serup-Hansen, E | 1 |
Andersen, LJ | 1 |
Lindeløv, B | 1 |
McCulloch, T | 1 |
Adimi, P | 1 |
Bastholt, L | 1 |
Ernst, T | 1 |
Merx, K | 1 |
Gnad-Vogt, U | 1 |
Lukan, N | 1 |
Kripp, M | 1 |
Schultheis, B | 1 |
Hochhaus, A | 1 |
Hofheinz, RD | 1 |
Milano, G | 1 |
Etienne-Grimaldi, MC | 1 |
Mari, M | 1 |
Lassalle, S | 1 |
Formento, JL | 1 |
Francoual, M | 1 |
Lacour, JP | 1 |
Hofman, P | 1 |
Jansen, GT | 1 |
Dillaha, CJ | 1 |
Honeycutt, WM | 1 |
Brenner, S | 1 |
Shohet, J | 1 |
Krakowski, A | 1 |
Ilie, B | 1 |
Carter, DM | 1 |
Balin, AK | 1 |
Bedikian, AY | 1 |
Bodey, GP | 1 |
Valdivieso, M | 1 |
Burgess, MA | 1 |
Ray, GR | 1 |
Fish, VJ | 1 |
Marmor, JB | 1 |
Rogoway, W | 1 |
Kushlan, P | 1 |
Arnold, C | 1 |
Lee, RH | 1 |
Marzoni, F | 1 |
Tsuji, T | 1 |
Nakagawa, K | 1 |
Hamada, T | 1 |
Bedwinek, JM | 1 |
Ratkin, GA | 1 |
Philpott, GW | 1 |
Wallack, M | 1 |
Perez, CA | 1 |
Heine, KG | 1 |
Goette, DK | 1 |
Eubanks, SW | 1 |
Gentry, RH | 1 |
Patterson, JW | 1 |
May, DL | 1 |
Benoldi, D | 1 |
Pezzarossa, E | 1 |
Alinovi, A | 1 |
Labrini, G | 1 |
Marcheselli, W | 1 |
de Panfilis, G | 1 |
Manfredi, G | 1 |
Noble, S | 1 |
Wagstaff, AJ | 1 |
Leo, S | 1 |
Tatulli, C | 1 |
Taveri, R | 1 |
Campanella, GA | 1 |
Carrieri, G | 1 |
Colucci, G | 1 |
Nelson, BR | 1 |
Kolansky, G | 1 |
Gillard, M | 1 |
Ratner, D | 1 |
Johnson, TM | 1 |
Landry, JC | 1 |
Koretz, MJ | 1 |
Wood, WC | 1 |
Bahri, S | 1 |
Smith, RG | 1 |
Costa, M | 1 |
Daneker, GW | 1 |
York, MR | 1 |
Sarma, PR | 1 |
Lynn, M | 1 |
McAtee, N | 1 |
Brooks, C | 1 |
Dela Rosa, T | 1 |
Singal, A | 1 |
Mohanty, S | 1 |
Bhattacharya, SN | 1 |
Baruah, MC | 1 |
Singh, N | 1 |
Gray, RJ | 1 |
Meland, NB | 1 |
Kim, JJ | 1 |
Chang, MW | 1 |
Shwayder, T | 1 |
Roth, AD | 1 |
Berney, CR | 1 |
Rohner, S | 1 |
Allal, AS | 1 |
Morel, P | 1 |
Marti, MC | 1 |
Aapro, MS | 1 |
Alberto, P | 1 |
Rees, RB | 2 |
Happle, R | 1 |
Dovzhanskiĭ, SI | 1 |
Suvorov, AP | 1 |
Breitbart, EW | 1 |
Hahn, P | 1 |
Hallberg, O | 1 |
Vikterlöf, KJ | 1 |
Wohlrab, W | 1 |
Lewis, MB | 1 |
Defiebre, BK | 1 |
Cohen, M | 1 |
Perry, HO | 1 |
Clemons, DE | 1 |
Aeling, JL | 1 |
Nuss, DD | 1 |
Ottolenghi, F | 1 |
Andreassi, L | 1 |
Sbano, E | 1 |
Fimiani, M | 1 |
Whittle, T | 1 |
Lucas, CE | 1 |
Ledgerwood, AM | 1 |
Weaver, A | 1 |
al-Sarraf, M | 1 |
Guan, ZX | 1 |
Grabow, D | 1 |
Nunnink, JC | 1 |
Krusinski, PA | 1 |
Yates, JW | 1 |
Larson, PO | 1 |
Tennstedt, D | 1 |
Lachapelle, JM | 1 |
Cobb, MW | 1 |
Pellegrini, AE | 1 |
Villani, C | 1 |
Pace, S | 1 |
Tomao, S | 1 |
Pietrangeli, D | 1 |
Pucci, G | 1 |
Bennett, R | 1 |
Epstein, E | 2 |
Goette, D | 1 |
Lowe, N | 1 |
Maibach, H | 1 |
Menn, H | 1 |
Tromovitch, T | 1 |
Bissada, NK | 1 |
Redman, JF | 1 |
Sulieman, JS | 1 |
Nevin, JE | 1 |
Melnick, I | 1 |
Baggerly, JT | 1 |
Estevez, J | 1 |
Landes, R | 1 |
Easley, CA | 1 |
Goldmann, L | 1 |
Igelman, JM | 1 |
Kitzmiller, K | 1 |
Lynch, PJ | 1 |
Stoughton, RB | 1 |
Richardson, JR | 1 |
Linton, PC | 1 |
Leadbetter, GW | 1 |
Weinstein, GD | 1 |
Zackheim, HS | 1 |
Farber, EM | 1 |
Bart, BJ | 1 |
Bean, SF | 1 |
Miller, E | 1 |
Yamamoto, K | 1 |
Sasaki, S | 1 |
Schuppli, R | 2 |
Spencer, SK | 1 |
Kierland, RR | 1 |
Midana, A | 1 |
Leigheb, G | 1 |
Erlanger, M | 1 |
Martz, G | 1 |
Ott, F | 1 |
Storck, H | 1 |
Rieder, J | 1 |
Kessler, S | 1 |
Nazzaro, P | 1 |
Alden, HS | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Efficacy of Topical 5-fluorouracil Versus Topical Latanoprost With Microneedling in Localized Stable Vitiligo: A Randomised Clinical Trial[NCT05513924] | Phase 2/Phase 3 | 40 participants (Actual) | Interventional | 2022-03-15 | Completed | ||
A Double-Blind, Randomized Phase 2b Study of Sorafenib Compared to Placebo When Administered in Combination With Chemotherapy for Patients With Locally Advanced or MBC That Has Progressed During or After Bevacizumab Therapy[NCT00493636] | Phase 2 | 160 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
A Randomized, Multicenter Phase 3 Study to Compare the Efficacy of Panitumumab in Combination With Chemotherapy to the Efficacy of Chemotherapy Alone in Patients With Previously Treated Metastatic Colorectal Cancer[NCT00339183] | Phase 3 | 1,186 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
Phase I, Dual Arm, Open-Label, Trial of Intralesional 5-Fluorouracil (5FU) and Intralesional 5FU Combined With Topical Imiquimod in Patients With Squamous Cell Carcinoma (SCC) of the Lower Extremities[NCT03370406] | Phase 1 | 30 participants (Anticipated) | Interventional | 2018-08-03 | Recruiting | ||
Comparison of 70% Pyruvic Acid Solution and Duofilm Solution in Treatment of Plantar Wart[NCT02151630] | Phase 2/Phase 3 | 60 participants (Anticipated) | Interventional | 2014-05-31 | Recruiting | ||
Evaluation of the Efficacy of Intralesional Injection of Combined Digoxin and Furosemide Versus 5 - Fluorouracil in Treatment of Plantar Warts[NCT05520658] | 60 participants (Anticipated) | Interventional | 2022-07-01 | Recruiting | |||
A Phase 2, Open-label, Randomized Clinical Trial of Skin Toxicity Treatment in Subjects Receiving Second-line FOLFIRI or Irinotecan Only Chemotherapy Concomitantly With Panitumumab[NCT00332163] | Phase 2 | 95 participants (Actual) | Interventional | 2006-04-30 | Completed | ||
A Single Arm Multicentre Phase II Study of Panitumumab in Combination With Irinotecan/5-fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer[NCT00508404] | Phase 2 | 154 participants (Actual) | Interventional | 2007-05-09 | Completed | ||
A Phase II, Randomised Controlled Trial to Evaluate the Efficacy and Safety of Moisturising Creams With or Without Palm-oil-derived Vitamin E Concentrate in Addition to Urea-based Cream or Urea-based Cream Alone in Capecitabine-associated Palmar-Plantar E[NCT05939726] | 90 participants (Anticipated) | Interventional | 2023-05-16 | Recruiting | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Duration of overall response was calculated as the time (days) from first documentation of CR or PR (whichever status is recorded first) until the first date that recurrent or progressive disease (PD) or death is objectively documented. Response was evaluated via changes from baseline in radiological tumor measurements using RECIST version 1.0 guidelines, where complete response (CR) is the disappearance of all target lesions; partial response (PR) is >=30% decrease in the sum of the longest diameter (LD) of target lesions; Stable Disease (SD) is neither sufficient shrinkage in sum of LD of target lesions to be PR nor increase of >=20%; Progressive Disease (PD) is the increase in existing lesions or new lesions. (NCT00493636)
Timeframe: Period measured from the first documentation of complete or partial response (whichever status is recorded first) until the first date that recurrent or progressive disease or death is objectively documented.
Intervention | Days (Median) |
---|---|
A (Sorafenib + Gemcitabine or Capecitabine) | 94 |
B (Placebo + Gemcitabine or Capecitabine) | 147 |
Overall response rate was defined as the proportion of participants experiencing complete response (CR) and partial response (PR) as best overall response. Response was evaluated via changes from baseline in radiological tumor measurements using RECIST version 1.0 guidelines, where complete response (CR) is the disappearance of all target lesions; partial response (PR) is >=30% decrease in the sum of the longest diameter (LD) of target lesions; Stable Disease (SD) is neither sufficient shrinkage in sum of LD of target lesions to be PR nor increase of >=20%; Progressive Disease (PD) is the increase in existing lesions or new lesions. (NCT00493636)
Timeframe: The overall tumor burden at baseline will be compared with subsequent measurements up to the date of first documented disease progression or the date of death due to any cause, if before progression, assessed up to 39 months.
Intervention | percentage of participants (Number) |
---|---|
A (Sorafenib + Gemcitabine or Capecitabine) | 19.8 |
B (Placebo + Gemcitabine or Capecitabine) | 12.7 |
(NCT00493636)
Timeframe: From the date of randomization to date of death due to any cause, assessed up to 56 months.
Intervention | Days (Median) |
---|---|
A (Sorafenib + Gemcitabine or Capecitabine) | 407 |
B (Placebo + Gemcitabine or Capecitabine) | 348 |
(NCT00493636)
Timeframe: From the date of randomization to date of first documented disease progression (i.e., the date on which a radiologic procedure or clinical evaluation was performed) or the date of death due to any cause, if before progression, assessed up to 39 months.
Intervention | Days (Median) |
---|---|
A (Sorafenib + Gemcitabine or Capecitabine) | 103 |
B (Placebo + Gemcitabine or Capecitabine) | 81 |
(NCT00493636)
Timeframe: Calculated as the time (days) from date of randomization to date of first observed disease progression (radiological or clinical, whichever is earlier), assessed up to 39 months.
Intervention | Days (Median) |
---|---|
A (Sorafenib + Gemcitabine or Capecitabine) | 111 |
B (Placebo + Gemcitabine or Capecitabine) | 82 |
"Calculated only for those participants with an objective response as the time from the first objective response (subsequently confirmed within no less than 4 weeks) to first observed disease progression per modified-RECIST criteria. Participants not meeting these criteria by the analysis data cutoff date were censored at their last evaluable disease assessment date.~Progressive disease is defined as a ≥ 20% increase in the size of target lesions or unequivocal progression of existing non-target lesions or any new lesions." (NCT00339183)
Timeframe: From randomization until the data cut-off date of 30 April 2009. Maximum follow-up time was 33 months
Intervention | months (Median) |
---|---|
Wild-type KRAS - Panitumumab Plus FOLFIRI | 7.6 |
Wild-type KRAS - FOLFIRI Alone | 6.6 |
Mutant KRAS - Panitumumab Plus FOLFIRI | 6.0 |
Mutant KRAS - FOLFIRI Alone | 7.4 |
Overall survival was defined as the time from randomization to the date of death. Participants who had not died by the analysis data cutoff date had their time of death censored at their last contact date. (NCT00339183)
Timeframe: From randomization until the data cut-off date of 30 April 2009. Maximum follow-up time was 33 months
Intervention | months (Median) |
---|---|
Wild-type KRAS - Panitumumab Plus FOLFIRI | 14.5 |
Wild-type KRAS - FOLFIRI Alone | 12.5 |
Mutant KRAS - Panitumumab Plus FOLFIRI | 11.8 |
Mutant KRAS - FOLFIRI Alone | 11.1 |
Participants were evaluated for tumor response per the modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria every 8 weeks until disease progression. Objective response was defined as the incidence of either a confirmed complete or partial response (CR or PR) while on study, as determined by blinded independent central review and confirmed no less than 4-weeks after the criteria for response are first met. CR: Disappearance of all target and non-target lesions and no new lesions. PR: At least a 30% decrease in the sum of the longest diameter of target lesions and no progression of non-target or no new lesions, or, disappearance of all target lesions and the persistence of ≥ 1 non-target lesion not qualifying for either CR or progressive disease. Participants without a post-baseline assessment were considered non-responders. (NCT00339183)
Timeframe: Every 8 weeks until disease progression up to the data cut-off date of 30 April 2009. Maximum time on follow-up was 33 months.
Intervention | percentage of participants (Number) |
---|---|
Wild-type KRAS - Panitumumab Plus FOLFIRI | 35.35 |
Wild-type KRAS - FOLFIRI Alone | 9.82 |
Mutant KRAS - Panitumumab Plus FOLFIRI | 13.36 |
Mutant KRAS - FOLFIRI Alone | 13.92 |
"Progression-free survival was defined as the time from randomization to first disease progression per modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria or death, based on independent central radiological assessment. Participants who were alive but did not meet criteria for progression by the data cutoff date were censored at their last evaluable disease assessment date.~Progressive disease is defined as a ≥ 20% increase in the size of target lesions or unequivocal progression of existing non-target lesions or any new lesions." (NCT00339183)
Timeframe: From randomization until the data cut-off date of 8 April 2008. Maximum follow-up time was 17 months.
Intervention | months (Median) |
---|---|
Wild-type KRAS - Panitumumab Plus FOLFIRI | 5.9 |
Wild-type KRAS - FOLFIRI Alone | 3.9 |
Mutant KRAS - Panitumumab Plus FOLFIRI | 5.0 |
Mutant KRAS - FOLFIRI Alone | 4.9 |
"Time to progression was defined as the time from the randomization date to the date of first observed disease progression per the modified RECIST criteria. Participants not meeting these criteria by the analysis data cutoff date were censored at their last evaluable disease assessment date.~Progressive disease is defined as a ≥ 20% increase in the size of target lesions or unequivocal progression of existing non-target lesions or any new lesions." (NCT00339183)
Timeframe: From randomization until the data cut-off date of 30 April 2009. Maximum follow-up time was 33 months
Intervention | months (Median) |
---|---|
Wild-type KRAS - Panitumumab Plus FOLFIRI | 7.3 |
Wild-type KRAS - FOLFIRI Alone | 5.3 |
Mutant KRAS - Panitumumab Plus FOLFIRI | 5.5 |
Mutant KRAS - FOLFIRI Alone | 5.5 |
"A serious adverse event (SAE) is defined by regulatory authorities as one that • is fatal • is life threatening (places the subject at immediate risk of death) • requires in-patient hospitalization or prolongation of existing hospitalization • results in persistent or significant disability/incapacity • is a congenital anomaly/birth defect • other significant medical hazard. The relationship of the adverse event to the study treatment was assessed by the Investigator by means of the question: Is there a reasonable possibility that the event may have been caused by the study treatment?" (NCT00339183)
Timeframe: From randomization until the data cut-off date of 30 April 2009. Maximum follow-up time was 33 months.
Intervention | participants (Number) | |||||
---|---|---|---|---|---|---|
Any adverse event | Serious adverse event | Leading to discontinuation of any study drug | Treatment-related adverse event (TRAE) | Serious treatment-related adverse event | TRAE leading to discontinuation of any study drug | |
FOLFIRI Alone | 573 | 175 | 64 | 542 | 90 | 34 |
Panitumumab Plus FOLFIRI | 584 | 232 | 123 | 577 | 124 | 97 |
Best overall response rate is defined as the percentage of participants with a complete response (CR) or partial response (PR) while on study. Tumor response was assessed by CT scan or MRI of the abdomen, pelvis, and all other sites of disease. Disease assessments were performed by central review according to the modified RECIST criteria. CR: Disappearance of all target and non-target lesions and no new lesions. PR: Either the disappearance of all target lesions with persistence of one or more non-target lesion(s) not qualifying for either CR or PD (≥ 25% increase in lesion size) and no new lesions, or, at least a 30% decrease in the size of target lesions with no progression of existing non-target lesions, and no new lesions. (NCT00332163)
Timeframe: Response was assessed at Weeks 9 and 13 and then every 8 weeks for the Q2W regimen, or at Weeks 10, 14, 22 and then every 9 weeks for the Q3W regimen until the end of treatment; median treatment duration was 13 and 17 weeks in each group respectively.
Intervention | percentage of participants (Number) |
---|---|
Pre-emptive Skin Treatment | 15 |
Reactive Skin Treatment | 11 |
Overall Survival is defined as the time from the date of randomization to the date of death. Participants who did not die while on study or who were lost-to-follow-up were censored at their last contact date. Overall survival was analyzed using all data regardless of whether it was collected during second- or third-line treatment. (NCT00332163)
Timeframe: From randomization until the end of study; median time on study was 31 weeks and 41 weeks in each treatment group respectively with a maximum time on study of 97 weeks.
Intervention | months (Median) |
---|---|
Pre-emptive Skin Treatment | 11.2 |
Reactive Skin Treatment | 13.6 |
"The percentage of participants who developed at least 1 incidence of ≥ grade 2 skin toxicities of any type during the 6-week skin treatment period. Analysis of this endpoint was based on adverse event data associated with the Skin and Subcutaneous Tissue Disorders system organ class. Adverse events were graded according to the National Cancer Institute (NCI) CTCAE version 3.0." (NCT00332163)
Timeframe: 6 weeks
Intervention | percentage of participants (Number) |
---|---|
Pre-emptive Skin Treatment | 40 |
Reactive Skin Treatment | 62 |
(NCT00332163)
Timeframe: 6 weeks
Intervention | percentage of participants (Number) |
---|---|
Pre-emptive Skin Treatment | 6 |
Reactive Skin Treatment | 11 |
Skin toxicities were assessed by the study clinician and graded according to the modified Common Toxicity Criteria for Adverse Events (CTCAE) v.3.0 Dermatology Toxicity Grading criteria, on a scale from Grade 1 (mild) to 4 (life-threatening). The specific skin toxicities of interest were pruritus, acneiform dermatitis, skin desquamation (also described as skin exfoliation), exfoliative dermatitis, paronychia, nail disorder, skin fissures, skin laceration, pruritic rash, pustular rash, skin infection, skin ulceration, and local infection. (NCT00332163)
Timeframe: 6 weeks
Intervention | percentage of participants (Number) |
---|---|
Pre-emptive Skin Treatment | 29 |
Reactive Skin Treatment | 62 |
Defined as the time from the date of randomization to the first date of observed disease progression or death due to any cause (whichever comes first). Participants who were alive and had not progressed while on study were censored at the date of last progression-free tumor assessment. (NCT00332163)
Timeframe: From randomization until the end of study; median time on study was 31 weeks and 41 weeks in each treatment group respectively with a maximum time on study of 97 weeks.
Intervention | months (Median) |
---|---|
Pre-emptive Skin Treatment | 4.7 |
Reactive Skin Treatment | 4.1 |
Tumor response was assessed by CT scan or MRI of the abdomen, pelvis, and all other sites of disease. Disease assessments were performed by central review according to the modified response evaluation criteria in solid tumors (RECIST). Disease control rate is defined as the percentage of participants with a CR, PR or stable disease (SD) at the Week 9/10 assessment visit and a corresponding response (CR or PR) confirmed at the Week 13/14 assessment visit for the Q2W/Q3W regimens. SD: Neither sufficient shrinkage or increase in target lesions to qualify for PR or PD, with no progression of non-target lesions and no new lesions. (NCT00332163)
Timeframe: Week 9 with confirmed response at Week 13 for the FOLFIRI and panitumumab Q2W regimen or at Week 10 with confirmed response at Week 14 for the irinotecan and panitumumab Q3W regimen.
Intervention | percentage of participants (Number) |
---|---|
Pre-emptive Skin Treatment | 63 |
Reactive Skin Treatment | 64 |
Tumor response was assessed by computed tomography (CT) scan or magnetic resonance imaging (MRI) of the abdomen, pelvis, and all other sites of disease. Disease assessments were performed by central review according to the modified response evaluation criteria in solid tumors (RECIST). Response rate is defined as the percentage of participants with a complete response (CR) or partial response (PR) at the Week 9/10 assessment visit and a corresponding CR or PR confirmed at the Week 13/14 assessment visit for the Q2W/Q3W regimens. CR: Disappearance of all target and non-target lesions and no new lesions. PR: Either the disappearance of all target lesions with persistence of one or more non-target lesion(s) not qualifying for either CR or progressive disease (PD; ≥ 25% increase in lesion size) and no new lesions, or, at least a 30% decrease in the size of target lesions with no progression of existing non-target lesions, and no new lesions. (NCT00332163)
Timeframe: Week 9 with confirmed response at Week 13 for the FOLFIRI and panitumumab Q2W regimen or at Week 10 with confirmed response at Week 14 for the irinotecan and panitumumab Q3W regimen.
Intervention | percentage of participants (Number) |
---|---|
Pre-emptive Skin Treatment | 6 |
Reactive Skin Treatment | 6 |
Time to the first most severe grade ≥ 2 of all the specific skin-related toxicities of interest was defined as the time from the first dose of panitumumab to the date of the first occurrence of the most severe specific ≥ grade 2 skin toxicity of interest during the 6-week skin treatment period. Participants who did not experience any specific skin-related toxicity of grade ≥ 2 were censored at their last skin toxicity assessment during the 6-week skin toxicity assessment period. Skin toxicities were assessed by the study clinician and graded according to the modified CTCAE v.3.0 Dermatology Toxicity Grading criteria, on a scale from Grade 1 (mild) to 4 (life-threatening). The specific skin toxicities of interest were pruritus, acneiform dermatitis, skin desquamation (also described as skin exfoliation), exfoliative dermatitis, paronychia, nail disorder, skin fissures, skin laceration, pruritic rash, pustular rash, skin infection, skin ulceration, and local infection. (NCT00332163)
Timeframe: 6 weeks
Intervention | weeks (Median) |
---|---|
Pre-emptive Skin Treatment | NA |
Reactive Skin Treatment | 2.7 |
The time to the first occurrence of specific grade 2 or higher skin toxicities of interest was defined as the time from the first dose of panitumumab to the date of first occurrence of specific ≥ grade 2 skin toxicities of interest. Participants who did not experience specific skin-related toxicities were censored at their last skin toxicity assessment during the skin toxicity assessment period. Skin toxicities were assessed by the study clinician and graded according to the modified CTCAE v.3.0 Dermatology Toxicity Grading criteria, on a scale from Grade 1 (mild) to 4 (life-threatening). The specific skin toxicities of interest were pruritus, acneiform dermatitis, skin desquamation (also described as skin exfoliation), exfoliative dermatitis, paronychia, nail disorder, skin fissures, skin laceration, pruritic rash, pustular rash, skin infection, skin ulceration, and local infection. (NCT00332163)
Timeframe: 6 weeks
Intervention | weeks (Median) |
---|---|
Pre-emptive Skin Treatment | NA |
Reactive Skin Treatment | 2.1 |
"Time from the date of randomization to the date of observed disease progression or death due to disease progression. Participants who did not have documented disease progression were censored at the date of last tumor assessment; participants who died for reasons other than disease progression while on study were censored at the date of death. PD: At least a 20% increase in the size of target lesions, recorded since the treatment started, or at least a 25% increase in size of non-target lesions and the lesion(s) measure > 10 mm in one dimension, or the appearance of one or more new lesions.~Time to progression was analyzed using the Kaplan-Meier method. This analysis excludes any data collected during follow-up for participants who began third-line treatment." (NCT00332163)
Timeframe: From randomization until the end of study; median time on study was 31 weeks and 41 weeks in each treatment group respectively with a maximum time on study of 97 weeks.
Intervention | months (Median) |
---|---|
Pre-emptive Skin Treatment | 4.9 |
Reactive Skin Treatment | 4.1 |
Time-to-treatment failure is defined as the time from the date of randomization to the first date of any of the following events: discontinuation of study therapy due to any reason (except for complete response and curative surgery), progression of disease, or death due to any cause. Participants who did not discontinue, who were still alive, and who did not have disease progression were censored at the date of last contact. Time to treatment failure was analyzed using the Kaplan-Meier method. (NCT00332163)
Timeframe: From randomization until the end of study; median time on study was 31 weeks and 41 weeks in each treatment group respectively with a maximum time on study of 97 weeks.
Intervention | months (Median) |
---|---|
Pre-emptive Skin Treatment | 3.1 |
Reactive Skin Treatment | 4.2 |
Skin-related quality of life was assessed using the DLQI. The DLQI questionnaire asks participants to evaluate the degree that their skin condition has affected their quality of life in the last week. Participants answer 10 questions on a scale from 0 (not at all) to 3 (very much); The DLQI score is calculated by summing the scores for all questions, resulting in a maximum of 30 and a minimum of 0; higher scores indicate a more impaired quality of life. (NCT00332163)
Timeframe: Baseline and Weeks 2, 3, 4, 5, 6 and 7
Intervention | units on a scale (Mean) | ||||||
---|---|---|---|---|---|---|---|
Baseline (n=46, 44) | Change from Baseline to Week 2 (n=42, 41) | Change from Baseline to Week 3 (n=44, 42) | Change from Baseline to Week 4 (n=42, 42) | Change from Baseline to Week 5 (n=44, 42) | Change from Baseline to Week 6 (n=42, 38) | Change from Baseline to Week 7 (n=40, 40) | |
Pre-emptive Skin Treatment | 0.3 | 0.7 | 1.3 | 1.7 | 1.3 | 1.6 | 2.0 |
Reactive Skin Treatment | 0.1 | 1.6 | 4.2 | 3.8 | 2.7 | 2.3 | 2.6 |
The percentage of participants with a most severe grade of 2, 3 or 4 specific skin toxicity of interest reported during the 6-week skin treatment period. Skin toxicities were assessed by the study clinician and graded according to the modified CTCAE v.3.0 Dermatology Toxicity Grading criteria, on a scale from Grade 1 (mild) to 4 (life-threatening). The specific skin toxicities of interest were pruritus, acneiform dermatitis, skin desquamation (also described as skin exfoliation), exfoliative dermatitis, paronychia, nail disorder, skin fissures, skin laceration, pruritic rash, pustular rash, skin infection, skin ulceration, and local infection. (NCT00332163)
Timeframe: 6 weeks
Intervention | percentage of participants (Number) | ||
---|---|---|---|
Grade 2 | Grade 3 | Grade 4 | |
Pre-emptive Skin Treatment | 23 | 6 | 0 |
Reactive Skin Treatment | 40 | 21 | 0 |
"The percentage of participants whose best response was either a complete or partial response or stable disease, based on modified RECIST v1.0 criteria as assessed by the Investigator.~Stable diease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD of target lesions and no progression of existing non-target lesions and no new lesions, or, the persistence of 1 or more non-target lesions not qualifying for either CR or PD if no target lesions were identified at Baseline." (NCT00508404)
Timeframe: Tumor response was assessed at Week 8 and every 8 weeks to Week 48 and 3 monthly thereafter until disease progression; median follow-up time was 34 weeks
Intervention | percentage of participants (Number) |
---|---|
Wild-type KRAS | 90.59 |
Mutant KRAS | 89.66 |
Duration of response was calculated only for those participants who had a confirmed complete or partial response, and is defined as the time from first confirmed response to first observed progression. For participants who responded and did not progress by the analysis data cut-off date, duration of response was censored at their last evaluable disease assessment date. Duration of response was analyzed using the Kaplan-Meier method. (NCT00508404)
Timeframe: Tumor response was assessed at Week 8 and every 8 weeks to Week 48 and 3 monthly thereafter until disease progression; median follow-up time was 34 weeks.
Intervention | months (Median) |
---|---|
Wild-type KRAS | 13.0 |
Mutant KRAS | 7.4 |
Duration of stable disease was calculated only for participants with a best response of stable disease and is defined as the time from enrollment to first observed PD. For participants who did not progress by the analysis data cut-off date, duration of SD was censored at their last evaluable disease assessment date. Duration of stable disease was estimated using Kaplan-Meier methods. (NCT00508404)
Timeframe: Tumor response was assessed at Week 8 and every 8 weeks to Week 48 and 3 monthly thereafter until disease progression; median follow-up time was 34 weeks.
Intervention | months (Median) |
---|---|
Wild-type KRAS | 5.9 |
Mutant KRAS | 6.1 |
The percentage of participants with a best response of complete response or partial response by Week 17. Disease assessments are based on investigator review of scans using modified RECIST V1.0 criteria. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met. Participants with no post-baseline assessment were considered non-responders. (NCT00508404)
Timeframe: Up to Week 17
Intervention | percentage of participants (Number) |
---|---|
Wild-type KRAS | 49.41 |
Mutant KRAS | 34.48 |
"Objective response rate is defined as the percentage of participants with a best response of complete response or partial response. Disease assessments are based on investigator review of scans using modified Response Evaluation Criteria in Solid Tumors (RECIST) V1.0 criteria. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met. Participants with no post-baseline assessment were considered non-responders.~Complete Response (CR): disappearance of all target and non-target lesions and no new lesions.~Partial Response (PR): At least a 30% decrease in the size of target lesions with no progression of non-target lesions and no new lesions, or, the disappearance of all target lesions but persistence of 1 or more non-target lesions not qualifying for either CR or progressive disease (PD) and no new lesions." (NCT00508404)
Timeframe: Tumor response was assessed at Week 8 and every 8 weeks to Week 48 and 3 monthly thereafter until disease progression; median follow-up time was 34 weeks
Intervention | percentage of participants (Number) |
---|---|
Wild-type KRAS | 56.47 |
Mutant KRAS | 37.93 |
Progression-free survival is the time from the date of enrollment to the date of first observed progression or death, whichever comes first. Participants who were alive and did not progress by the analysis data cut-off date were censored at the last evaluable disease assessment date. Progression-free survival was analyzed using Kaplan-Meier methods. (NCT00508404)
Timeframe: From enrollment until the data cut-off date of 18 June 2009; median follow-up time was 34 weeks.
Intervention | months (Median) |
---|---|
Wild-type KRAS | 8.9 |
Mutant KRAS | 7.2 |
The percentage of participants who underwent a surgical procedure that resulted in partial reduction or complete eradication of all metastatic disease. (NCT00508404)
Timeframe: From enrollment until the data cut-off date of 18 June 2009; median follow-up time was 34 weeks.
Intervention | percentage of participants (Number) |
---|---|
Wild-type KRAS | 15.12 |
Mutant KRAS | 6.78 |
Time to progression is the time from the enrollment date to the date of first observed progression. For participants who had not progressed by the analysis data cutoff date, time to progressive disease was censored at their last evaluable disease assessment date. Time to disease progression was analyzed using Kaplan-Meier methods. (NCT00508404)
Timeframe: From enrollment until the data cut-off date of 18 June 2009; median follow-up time was 34 weeks.
Intervention | months (Median) |
---|---|
Wild-type KRAS | 11.2 |
Mutant KRAS | 7.3 |
Calculated only for those participants who underwent surgical intervention, and defined as the time from the date of first post-intervention radiographic disease assessment to the date of first observed PD. Participants with no post-intervention disease assessment had their time to relapse set to zero and censored in the analysis. Participants that had evidence of progression / recurrence at their first post-intervention disease assessment had a time to relapse of zero. For participants who had not progressed by the analysis data cut-off date, time to relapse was censored at the date of their last evaluable disease assessment. Time to relapse was analyzed using Kaplan-Meier metjhods. (NCT00508404)
Timeframe: From enrollment until the data cut-off date of 18 June 2009; median follow-up time was 34 weeks.
Intervention | months (Median) |
---|---|
Wild-type KRAS | NA |
Mutant KRAS | NA |
Time to response is the time from the date of enrollment to the date of first confirmed complete or partial response. Participants with a best response of stable disease at the analysis data cut-off date were censored at their last assessment of SD and participants with all other categories of best response were censored at the maximum observed time to a first confirmed response among all responders. Time to initial objective response was analyzed using Kaplan-Meier methods. (NCT00508404)
Timeframe: Tumor response was assessed at Week 8 and every 8 weeks to Week 48 and 3 monthly thereafter until disease progression; median follow-up time was 34 weeks.
Intervention | months (Median) |
---|---|
Wild-type KRAS | 3.8 |
Mutant KRAS | NA |
Time to treatment failure is defined as the time from enrollment to the date the decision was made to end the treatment phase for any reason. For participants who remained in the treatment phase at the analysis data cut-off date, time to treatment failure was censored at the date of their last on-study assessment. Time to treatment failure was analyzed using Kaplan-Meier methods. (NCT00508404)
Timeframe: From enrollment until the data cut-off date of 18 June 2009; median follow-up time was 34 weeks.
Intervention | months (Median) |
---|---|
Wild-type KRAS | 6.9 |
Mutant KRAS | 5.8 |
21 reviews available for fluorouracil and Dermatoses
Article | Year |
---|---|
5-Fluorouracil in Dermatology: The Diverse Uses Beyond Malignant and Premalignant Skin Disease.
Topics: Adrenal Cortex Hormones; Cicatrix; Combined Modality Therapy; Cosmetic Techniques; Dermatitis; Derma | 2021 |
Opportunities for laser-assisted drug delivery in the treatment of cutaneous disorders.
Topics: Administration, Cutaneous; Anesthetics, Local; Antineoplastic Agents; Cicatrix; Cosmetic Techniques; | 2017 |
Intralesional and Laser-Assisted 5-Fluorouracil in Dermatologic Disease: A Systematic Review.
Topics: Animals; Antimetabolites, Antineoplastic; Cicatrix, Hypertrophic; Fluorouracil; Humans; Injections, | 2018 |
Topical 5-fluorouracil in dermatologic disease.
Topics: Antimetabolites, Antineoplastic; Fluorouracil; Humans; Skin Diseases | 2018 |
Pharmacogenetics in dermatology: a patient-centered update.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineo | 2013 |
Analysis of dermatologic events in patients with cancer treated with lapatinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinic | 2009 |
Current combination chemotherapy regimens for metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineop | 2009 |
Clinical applications for topical 5-fluorouracil in the treatment of dermatological disorders.
Topics: Administration, Cutaneous; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Clinical Trials as Topic | 2009 |
Mechanisms of action of topical 5-fluorouracil: review and implications for the treatment of dermatological disorders.
Topics: Antimetabolites, Antineoplastic; Fluorouracil; Skin Diseases | 2012 |
Efficacy of topical treatments for cutaneous warts: a meta-analysis and pooled analysis of randomized controlled trials.
Topics: Administration, Topical; Adult; Anti-Infective Agents; Antibiotics, Antineoplastic; Antimetabolites, | 2011 |
Efficacy of topical treatments for cutaneous warts: a meta-analysis and pooled analysis of randomized controlled trials.
Topics: Administration, Topical; Adult; Anti-Infective Agents; Antibiotics, Antineoplastic; Antimetabolites, | 2011 |
Efficacy of topical treatments for cutaneous warts: a meta-analysis and pooled analysis of randomized controlled trials.
Topics: Administration, Topical; Adult; Anti-Infective Agents; Antibiotics, Antineoplastic; Antimetabolites, | 2011 |
Efficacy of topical treatments for cutaneous warts: a meta-analysis and pooled analysis of randomized controlled trials.
Topics: Administration, Topical; Adult; Anti-Infective Agents; Antibiotics, Antineoplastic; Antimetabolites, | 2011 |
Topical antineoplastic agents in the treatment of mucocutaneous diseases.
Topics: Administration, Topical; Aminoquinolines; Antineoplastic Agents; Diterpenes; Fluorouracil; Humans; I | 2011 |
Photodynamic therapy.
Topics: Administration, Topical; Aminolevulinic Acid; Antimetabolites, Antineoplastic; Cryotherapy; Fluorour | 2005 |
Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Clinical Trials, Phase | 2005 |
Dermatological aspects of aging.
Topics: Adult; Aged; Aging; Animals; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Dermatitis; Female; Fl | 1983 |
Topical chemotherapy with 5-fluorouracil. A review.
Topics: Administration, Topical; Chemical Phenomena; Chemistry; Dermatitis, Atopic; Dermatitis, Contact; Fem | 1981 |
Tretinoin. A review of its pharmacological properties and clinical efficacy in the topical treatment of photodamaged skin.
Topics: Administration, Topical; Animals; Cell Transformation, Neoplastic; Clinical Trials as Topic; Drug Th | 1995 |
Current dermatologic therapy.
Topics: Acne Vulgaris; Administration, Topical; Adrenal Cortex Hormones; Anti-Bacterial Agents; Antifungal A | 1976 |
Newer treatment in dermatology.
Topics: Acne Vulgaris; Adrenal Cortex Hormones; Antifungal Agents; Antineoplastic Agents; Carotenoids; Derma | 1975 |
The action of antimetabolites in the skin: methotrexate for psoriasis.
Topics: Carcinoma, Basal Cell; Cell Division; DNA; Fluorouracil; Humans; Injections, Intradermal; Keratosis; | 1972 |
Topical antimetabolites.
Topics: Antimetabolites; Antineoplastic Agents; Carcinoma, Basal Cell; Fluorouracil; Folic Acid Antagonists; | 1970 |
The metabolism and pharmacology of 5-fluorouracil.
Topics: Adenocarcinoma; Alopecia; Animals; Breast Neoplasms; Carbon Isotopes; Cell Division; Chromosome Aber | 1971 |
13 trials available for fluorouracil and Dermatoses
Article | Year |
---|---|
Efficacy of a global supportive skin care programme with hydrotherapy after non-metastatic breast cancer treatment: A randomised, controlled study.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; | 2018 |
Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2013 |
Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2014 |
Severe skin toxicity observed with the combination of capecitabine and weekly paclitaxel in metastatic breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Dose- | 2008 |
Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2011 |
The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2011 |
Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2012 |
Investigation into the usefulness and adverse events of CDDP, 5-fU and dl-leucovorin (PFL-therapy) for advanced colorectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Cisp | 2002 |
Whole-body hyperthermia in the scope of von Ardenne's systemic cancer multistep therapy (sCMT) combined with chemotherapy in patients with metastatic colorectal cancer: a phase I/II study.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemoth | 2004 |
A phase II study using vinorelbine and continuous 5-fluorouracil in patients with advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Catheterizati | 2007 |
Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Di | 2007 |
Intra-arterial chemotherapy in locally advanced or recurrent carcinomas of the penis and anal canal: an active treatment modality with curative potential.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Anus Neoplasms; Arteries; Bleo | 2000 |
[Controlled clinical studies of a new wart medication based on fluorouracil].
Topics: Adolescent; Adult; Aged; Baths; Child; Child, Preschool; Chronic Disease; Clinical Trials as Topic; | 1979 |
70 other studies available for fluorouracil and Dermatoses
Article | Year |
---|---|
Surfer with Photodistributed Erythematous, Scaling Eruption.
Topics: Animal Scales; Animals; Fluorouracil; Humans; Immunosuppressive Agents; Male; Middle Aged; Skin Dise | 2021 |
Cetuximab severe cutaneous toxicity… a gateway for bacteremia: case report.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Cellulitis; Cetu | 2023 |
Severe necrotising inflammatory skin reaction to topical 5-fluorouracil.
Topics: Administration, Ophthalmic; Antimetabolites, Antineoplastic; Conjunctival Neoplasms; Drug Eruptions; | 2019 |
A novel method to enhance efficacy of topical drugs by condom occlusion in penile dermatoses.
Topics: Administration, Topical; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Balanitis; Condo | 2020 |
EGFRI-associated health-related quality of life by severity of skin toxicity in metastatic colorectal cancer patients receiving epidermal growth factor receptor inhibitor target therapy.
Topics: Acneiform Eruptions; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; | 2020 |
Skin Disorders and Primary Tumor Location as Prognostic Factors in Patients with Metastatic Colorectal Cancer Treated with Cetuximab and Chemotherapy
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; | 2018 |
Comparative assessment of skin and subcutaneous toxicity in patients of advanced colorectal carcinoma treated with different schedules of FOLFOX.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2013 |
Intensity-Modulated Radiotherapy (IMRT) vs Helical Tomotherapy (HT) in Concurrent Chemoradiotherapy (CRT) for Patients with Anal Canal Carcinoma (ACC): an analysis of dose distribution and toxicities.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chem | 2015 |
Coincidential successful treatment of Jessner-Kanof disease with chemotherapy.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylati | 2008 |
[Management of hand-foot syndrome in patient treated with capecitabine].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil | 2008 |
[A case report of a patient with hand-foot syndrome induced by bolus 5-fluorouracil therapy].
Topics: Antineoplastic Agents; Chemistry, Pharmaceutical; Fluorouracil; Foot; Hand; Humans; Male; Middle Age | 2008 |
An unusual presentation of hand-foot syndrome at the hidden area: the scrotum and penis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administration Schedul | 2009 |
Perforating dermatosis in a patient receiving bevacizumab.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2009 |
Intralesional use of 5-FU in subcutaneous fibrosis.
Topics: Adult; Female; Fluorouracil; Humans; Injections, Intralesional; Male; Middle Aged; Skin Diseases | 2003 |
Combined 5-fluorouracil and Er:YAG laser treatment in a case of recurrent giant keratoacanthoma of the lower leg.
Topics: Administration, Cutaneous; Antimetabolites, Antineoplastic; Combined Modality Therapy; Diagnosis, Di | 2004 |
Response of predominantly recalcitrant cutaneous warts to topical chemotherapy.
Topics: Administration, Cutaneous; Deoxyglucose; Drug Therapy, Combination; Fluorouracil; Humans; Keratolyti | 2006 |
Keratoacanthoma centrifugum marginatum: response to topical 5-fluorouracil.
Topics: Aged, 80 and over; Dermatologic Agents; Female; Fluorouracil; Humans; Keratoacanthoma; Leg; Methotre | 2006 |
Multiple periungual pyogenic granulomas following systemic 5-fluorouracil.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Diagnosis, Differential; Fluorouracil; Granul | 2006 |
Bazex syndrome (acrokeratosis paraneoplastica).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Ear, External; | 2007 |
Candidate mechanisms for capecitabine-related hand-foot syndrome.
Topics: Adult; Antimetabolites, Antineoplastic; Biopsy; Capecitabine; Cell Proliferation; Deoxycytidine; Fem | 2008 |
Bowenoid conditions of the skin: treatment with topical 5-fluorouracil.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Male; Middle Aged; Skin Disease | 1967 |
Mucoid milia.
Topics: Aged; Epidermal Cyst; Female; Fluorouracil; Glycosaminoglycans; Humans; Skin Diseases | 1984 |
Phase I evaluation of oral tegafur.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Blood Cell Count; Diarrhea; Dose-Response Relatio | 1983 |
Impact of adjuvant chemotherapy on cosmesis and complications in stages I and II carcinoma of the breast treated by biopsy and radiation therapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Diseases; Breast Neoplasms; Ca | 1984 |
Different effects of topically applied 5-fluorouracil on hairy and hairless mice.
Topics: Animals; Dihydroxyphenylalanine; Fluorouracil; Hyperplasia; Hypertrophy; Melanocytes; Mice; Mice, Ha | 1984 |
Concurrent chemotherapy and radiotherapy for nonmetastatic, Stage IV breast cancer. A pilot study by the Southeastern Cancer Study Group.
Topics: Aged; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Therapy, C | 1983 |
Treatment of multiple keratoacanthomas with fluorouracil.
Topics: Arm; Fluorouracil; Hand Dermatoses; Humans; Keratoacanthoma; Male; Middle Aged; Skin Diseases | 1983 |
Treatment of multiple keratoacanthomas with intralesional fluorouracil.
Topics: Fluorouracil; Humans; Keratoacanthoma; Male; Middle Aged; Recurrence; Skin Diseases | 1982 |
[Retinoic acid and 5-FU mixture in the topical treatment of several skin diseases (author's transl)].
Topics: Drug Combinations; Fluorouracil; Humans; Keratosis; Ointments; Radiation Injuries; Skin Diseases; Sy | 1980 |
Dermatological toxicity from chemotherapy containing 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Rel | 1994 |
Management of linear verrucous epidermal nevus with topical 5-fluorouracil and tretinoin.
Topics: Administration, Topical; Child; Fluorouracil; Hamartoma; Humans; Male; Neck; Occlusive Dressings; Sk | 1994 |
Preoperative irradiation and fluorouracil chemotherapy for locally advanced rectosigmoid carcinoma: phase I-II study.
Topics: Adult; Aged; Combined Modality Therapy; Female; Fluorouracil; Gastrointestinal Diseases; Humans; Mal | 1993 |
Cryotherapy reduces fluorouracil-related side effects.
Topics: Adult; Antimetabolites, Antineoplastic; Colostomy; Cryotherapy; Female; Fluorouracil; Humans; Male; | 1995 |
Unusual multiple keratoacanthoma in a child successfully treated with 5-fluorouracil.
Topics: Administration, Topical; Antimetabolites, Antineoplastic; Child, Preschool; Fluorouracil; Humans; In | 1997 |
Topical 5-fluorouracil as primary therapy for keratoacanthoma.
Topics: Administration, Topical; Aged; Aged, 80 and over; Antimetabolites; Fluorouracil; Humans; Keratoacant | 2000 |
Topical tretinoin and 5-fluorouracil in the treatment of linear verrucous epidermal nevus.
Topics: Antimetabolites; Child; Drug Combinations; Fluorouracil; Hamartoma; Humans; Keratolytic Agents; Male | 2000 |
[Advances in topical therapy of skin diseases (author's transl)].
Topics: Acne Vulgaris; Administration, Topical; Alopecia; Benzoyl Peroxide; Dinitrochlorobenzene; Fluocortol | 1979 |
[Use of fluorafur in the therapy of various chronic dermatoses].
Topics: Adult; Aged; Chronic Disease; Fluorouracil; Humans; Male; Middle Aged; Neurodermatitis; Psoriasis; S | 1977 |
Acute skin reactions in postoperative breast cancer patients receiving radiotherapy plus adjuvant chemotherapy.
Topics: Breast Neoplasms; Cobalt Radioisotopes; Cyclophosphamide; Drug Therapy, Combination; Drug-Related Si | 1978 |
[Effect of urea on the mechanism of percutaneous permeation].
Topics: Animals; Autoradiography; Drug Therapy, Combination; Epidermis; Fluorouracil; Guinea Pigs; Skin Abso | 1979 |
A short survey on the use and efficacy of 5-fluorouracil in Australia.
Topics: Aged; Australia; Carcinoma, Basal Cell; Fluorouracil; Humans; Keratosis; Skin Diseases; Skin Neoplas | 1978 |
Bowen's disease of the nail bed: a case presentation and review of the literature.
Topics: Bowen's Disease; Carcinoma, Squamous Cell; Dermatologic Agents; Fluorouracil; Humans; Keratolytic Ag | 1978 |
Local chemotherapy of skin.
Topics: Fluorouracil; Humans; Skin Diseases; Skin Neoplasms | 1979 |
Management of skin blemishes.
Topics: Aged; Electrosurgery; Fluorouracil; Humans; Keratosis; Male; Middle Aged; Skin; Skin Diseases | 1977 |
Letter: Dermatitis medicamentosa: a pitfall for the unwary.
Topics: Adult; Female; Fluorouracil; Humans; Medication Errors; Skin Diseases | 1976 |
[Diffuse chronic mucocutaneous candidiasis: Effects of antimycotics in vitro].
Topics: Amphotericin B; Antifungal Agents; Candida; Candidiasis, Cutaneous; Candidiasis, Oral; Child; Chroni | 1975 |
The effects of chemotherapy on murine wound healing and orocutaneous fistula closure.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fistula; Fluorouracil; Male; Mou | 1990 |
Multicentric reticulohistiocytosis and cancer: a case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arthritis; Breast Neoplasms; Carcinoma, Intraductal, | 1985 |
Keratoacanthomas treated with Mohs' micrographic surgery (chemosurgery). A review of forty-three cases.
Topics: Aged; Aged, 80 and over; Female; Fluorouracil; Humans; Keratoacanthoma; Male; Microsurgery; Middle A | 1987 |
Allergic contact dermatitis to 5-fluorouracil.
Topics: Adult; Drug Eruptions; Fluorouracil; Humans; Male; Skin Diseases; Warts | 1987 |
Squamous cell carcinoma following fluorouracil-responsive 'keratoacanthoma'.
Topics: Aged; Carcinoma, Squamous Cell; Diagnostic Errors; Fluorouracil; Humans; Keratoacanthoma; Male; Skin | 1987 |
Skin necrosis due to antiblastics (procedures of prevention and therapy).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Ext | 1986 |
Current management using 5-fluorouracil: 1985.
Topics: Administration, Topical; Female; Fluorouracil; Humans; Male; Skin Diseases; Skin Neoplasms | 1985 |
Condyloma acuminatum of male urethra. Successful management with 5-fluorouracil.
Topics: Adult; Condylomata Acuminata; Diverticulum; Fistula; Fluorouracil; Humans; Male; Neoplasm Recurrence | 1974 |
Arterial infusion of 5-fluorouracil as a treatment for carcinoma of the prostate.
Topics: Aged; Catheterization; Fluorouracil; Humans; Iliac Artery; Injections, Intra-Arterial; Male; Middle | 1974 |
Investigative studies with DMSO in dermatology.
Topics: Animals; Dermatomycoses; Dimethyl Sulfoxide; Drug Eruptions; Fluocinolone Acetonide; Fluorouracil; G | 1967 |
Tumors of the skin. Premalignment and malignant.
Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Diagnosis, Differential; Fluorouracil; Humans; Kera | 1974 |
Status of topical therapy.
Topics: Administration, Topical; Anti-Inflammatory Agents; Biopharmaceutics; Fluorouracil; Glucocorticoids; | 1974 |
A new concept in the treatment of stomal stenosis.
Topics: Cesium Isotopes; Child; Cicatrix; Fluorouracil; Humans; Ileum; Male; Mucus; Skin Diseases; Skin Tran | 1972 |
Fluorouracil cream (Efudix) in dermatology.
Topics: Fluorouracil; Humans; Keratosis; Psoriasis; Skin Diseases; Skin Neoplasms; Xeroderma Pigmentosum | 1973 |
Bullous pemphigoid following the topical use of fluorouracil.
Topics: Aged; Autoantibodies; Fluorescent Antibody Technique; Fluorouracil; Humans; Keratosis; Male; Skin Di | 1970 |
[Therapeutic effects of 5-florouracil ointment on various skin diseases].
Topics: Adolescent; Adult; Aged; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Female; Fluorouracil; Huma | 1972 |
Treatment of precancerous dermatoses with topical 5-Fluorouracil.
Topics: Fluorouracil; Humans; Keratosis; Ointments; Precancerous Conditions; Skin Diseases; Solutions | 1969 |
[Practical use of immunosuppressive and cytostatic drugs in dermatological diseases].
Topics: Antineoplastic Agents; Azathioprine; Condylomata Acuminata; Fluorouracil; Humans; Immunosuppressive | 1970 |
The aging skin: problems and their causes.
Topics: Aged; Aging; Arsenicals; Balanitis; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Female; Fluorou | 1970 |
[Treatment of dermatologic lesions using immunosuppressive agents and cytostatics].
Topics: Antineoplastic Agents; Azathioprine; Dermatomyositis; Fluorouracil; Humans; Immunosuppressive Agents | 1970 |
5-fluorouracil (5-FU) ointment in the treatment of benign and malignant skin lesions.
Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Fluorouracil; Humans; Keratoacanthoma; Keratosis; L | 1970 |
Cutaneous absorption and urinary excretion of 6-14C-5-fluorouracil ointment applicated in an ointment to healthy and diseased human skin.
Topics: Adolescent; Aged; Carbon Isotopes; Female; Fluorouracil; Humans; Male; Middle Aged; Ointments; Skin | 1970 |
[Dermatologic aspects of cutaneous pseudocancer].
Topics: Colchicine; Diagnosis, Differential; Fluorouracil; Humans; Keratoacanthoma; Podophyllin; Skin Diseas | 1971 |
Antimetabolites in the treatment of skin disease.
Topics: Antimetabolites; Fluorouracil; Humans; Methotrexate; Skin Diseases; Skin Neoplasms | 1968 |